IONS: ionispharma.com Earnings per share for the last twelve months

Graphic logo of Ionis Pharmaceuticals, Inc. (IONS)

Ionis Pharmaceuticals (IONS) generates revenue from treating rare pathologies, securing a multi-year income stream. However, the cost of trials and the probability of late-stage failures create certain challenges. Fundamental TTM earnings per share clearly demonstrate the business's market sensitivity, while the -3.34 metric confirms the current level. The company's resilience is based on unique patents and strict FDA control.

IONS (Isis Pharmaceuticals) Earnings per share for the trailing year history from 07/04/2022 to 11/14/2026

Analytical breakdowns for Ionis Pharmaceuticals, Inc. (IONS)

- share price and expert price forecast:
Stock Quotes Ionis Pharmaceuticals|IONS - Fair Value Consensus
- market capitalization information:
Market Value Ionis Pharmaceuticals|IONS - Full Business Value
- shareholders' equity book value data:
Book Value per Share Ionis|IONS - Accounting Value of Company|Market Capitalization to Book Value Ratio ionispharma.com|IONS - Company Total Assets
- debt and solvency information:
Debt to Equity Ionis Pharmaceuticals|IONS - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ionis Pharma|IONS - Company Total Debt|Debts to Book Capitalization Ionis Pharmaceuticals|IONS - Company Long-Term Debts|Company Short-Term Debts Ionis|Quick Ratio ionispharma.com
- net income and valuation multiples indicators:
IONS - Company Net Income|Future Profit Ionis Pharmaceuticals|IONS - P/E Multiple|Projected Price to Earnings Ionis|IONS - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Ionis Pharmaceuticals|IONS - Operating income before deduction of amortization|Net earnings per share (EPS TTM) Ionis|IONS - Net earnings per share for the last 12 months|Quarterly EPS earnings growth ionispharma.com|IONS - Earnings growth in current year|Net earnings per share growth forecast for next year Ionis Pharmaceuticals
- issuer revenue and sales details:
IONS - Company Revenue|Company Projected Revenue Ionis Pharmaceuticals|IONS - Price-to-Revenue Coefficient|Forward P/S Multiple Ionis Pharmaceuticals
Initial company analysis:Ionis Pharmaceuticals (IONS)
Mass-produced product of Ionis Pharma

Annual net income per share determines the actual return of each security by dividing the company's final financial result by the total number of issued shares. By analyzing the annual net income per share chart, an investor can assess the effectiveness of Brett Monaiya's strategy at Ionis Pharmaceuticals (IONS) regarding the commercialization of innovative RNA drugs and the reduction of costs associated with payments to external licensees.

Competitors of Ionis Pharmaceuticals (IONS)

TEM: Net earnings per share for the last 12 months|Earnings per share for the trailing year QGEN (qiagen.com)|Repligen (RGEN) - Earnings per share for the last twelve months|Earnings per one share for the last 12 months RNA (Avidity Biosciences Inc)|CRSP (CRISPR Therapeutics Corp) - Net earnings per share (EPS TTM)|WGS: Earnings per share for the trailing year|Net earnings per share (EPS TTM) RARE|Net earnings per share (EPS TTM) beamtx.com (BEAM)|Earnings per share for the last twelve months Sarepta SRPT|Earnings per share for the trailing year TWST|TXG - Earnings per share for the last twelve months|Intellia Corp (NTLA) - Net earnings per share for the last 12 months|STOK: Net earnings per share (EPS TTM)|biolifesolutions.com (BLFS) - Net earnings per share (EPS TTM)|WVE (Wave Life Sciences Ltd.) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Maze Therapeutics, Inc. (MAZE)|Net earnings per share (EPS TTM) SION|PRME - Net earnings per one share for the last twelve months|Taysha Gene Therapies - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) uniqure.com QURE|MGTX: Net earnings per share for the last 12 months|REGENXBIO Inc - Earnings per share for the last four quarters|SLDB: Net earnings per share (EPS TTM)|OCGN - Net earnings per share for the last four quarters|PACB (Pacific Biosciences) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months benitec.com (BNTC)|Net earnings per share (EPS TTM) DSGN|Net earnings per share (EPS TTM) Rocket Pharma (RCKT)|Earnings per share for the last twelve months 4D Molecular Therapeutics Inc FDMT|Lexeo Therapeutics Inc. - Earnings per share for the last twelve months|KRRO - Earnings per share for the last twelve months|Net earnings per share for the last four quarters editasmedicine.com EDIT|SLN: Net earnings per share (EPS TTM)|PRQR - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Codexis Inc|Net earnings per one share for the last twelve months Sangamo BioSciences SGMO|Earnings per share for the last twelve months Nautilus Biotechnology (NAUT)|metagenomi.co - Earnings per share for the last 12 months|Earnings per share for the last twelve months Precision BioSciences, Inc. DTIL|Net earnings per share for the last four quarters Generation Bio Co (GBIO)|Boundless Bio, Inc - Net earnings per share (EPS TTM)|XCUR (Exicure, Inc.) - Earnings per share for the last 12 months|imunon.com (IMNN) - Earnings per share for the last twelve months|Earnings per share for the last 12 months PHIO|MBIO (Mustang Bio Inc) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) TransCode|Net earnings per share (EPS TTM) BNGO|Net earnings per share for the last four quarters Applied DNA Corp|Earnings per share for the last twelve months bluebird bio, Inc. BLUE|ImmunoPrecise Antibodies Ltd (IPA) - Net earnings per one share for the last twelve months|OMGA - Earnings per share for the last twelve months|OMIC (Singular Genomics Systems, Inc.) - Earnings per share for the last 12 months|RGLS: Net earnings per share (EPS TTM)|SYRS - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Telesis Bio, Inc.|traconpharma.com (TCON) - Net earnings per share for the last four quarters|Net earnings per share for the last 12 months UBX (Unity Biotechnology, Inc.)